new version V2017

immune checkpoint inhibition
Description Results

Atezolizumab - Avelumab - Durvalumab - Durvalumab + tremelimumab - Ipilimumab - Nivolumab - Pembrolizumab      

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

gastric or gastro-oesophageal junction cancer (advanced)

nivolumab
ATTRACTION-2, 2017nivolumabplacebo Low risk of bias SuggestingNCT02267343
pembrolizumab
KEYNOTE-059pembrolizumabnil - NCT02335411
Keynote 061, 2018pembrolizumabpaclitaxel2L Risk of bias Negative NCT02370498

Head and neck cancer

durvalumab
Hawk ongoing durvalumabstandard treatment2L PD-L1 positive - NCT02207530
durvalumab + tremelimumab
Eagle ongoing durvalumab +/- tremelimumabstandard treatment2L - NCT02369874
Condor ongoing durvalumab +/- tremelimumabstandard treatment2L PD-L1 positive - NCT02319044
Kestrel ongoing durvalumab +/- tremelimumabstandard treatment1L - NCT02551159
nivolumab
Checkmate-141, 2016nivolumabstandard treatment2L Risk of bias ConclusiveNCT02105636
Checkmate-651 ongoing nivolumab + ipilumabstandard treatment1L - NCT02741570
pembrolizumab
KEYNOTE-040pembrolizumabstandard treatment2L Risk of bias SuggestingNCT02252042
KEYNOTE-048 ongoing pembrolizumabCetuximab + Platinum + 5FU1L - NCT02358031
Keynote 147 ongoing pembrolizumab +/- acalabrutinibstandard treatment>2L - NCT02454179

lung cancer (metastatic)

atezolizumab
POPLAR Phase 2 atezolizumab, 2016atezolizumabdocetaxel2L Exploratory NegativeNCT01903993
OAK, 2016atezolizumabdocetaxel2L Risk of bias SuggestingNCT02008227
IMpower150 (WT), 2018atezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L Risk of bias SuggestingNCT02366143
IMpower150 (Teff), 2018atezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, TeffSuggestingNCT02366143
IMpower 010 ongoing atezolizumabBest Supportive Care - NCT02486718
IMpower 210 ongoing atezolizumabdocetaxel - NCT02813785
IMpower 133 ongoing atezolizumab + platinum-based CTplatinum-based CT1L - NCT02763579
IMpower 132 ongoing atezolizumab + platinum-based CTplatinum-based CT1L - NCT02657434
IMpower 131 ongoing atezolizumab + platinum-based CTplatinum-based CT - NCT02367794
GO29432 ongoing atezolizumabplatinum-based CT1L Risk of bias - NCT02409355
IMpower 110 ongoing atezolizumabplatinum-based CT1L Risk of bias - NCT02409342
avelumab
JAVELIN Lung 200 ongoing avelumabdocetaxel2L, PDL1 positive Risk of bias - NCT02395172
JAVELIN Lung 100 ongoing avelumabplatinum-based CT1L, PDL1 positive Risk of bias - NCT02576574
durvalumab
PACIFIC, 2017durvalumabplacebomaintenance Low risk of bias ConclusiveNCT02125461
ARCTIC PD-L1 negative, 2018durvalumab + tremelimumabStandard of Care3L, PD-L1 negative - NCT02352948
NEPTUNE ongoing durvalumab + tremelimumabplatinum-based CT1L Risk of bias - NCT02542293
CAURAL ongoing durvalumab + osimertinibosimertinib2L after EGFR TKI, T790M positive Risk of bias - NCT02454933
NCT02273375 ongoing durvalumabplaceboadjuvant Low risk of bias - NCT02273375
MYSTIC (combination) ongoing durvalumab +tremelimumabStandard of Care1L Risk of bias - NCT02453282
MYSTIC (monotherapy) ongoing durvalumabStandard of Care1L Risk of bias - NCT02453282
ARCTIC PD-L1 positive ongoing durvalumabStandard of Care>2L, PDL1 positive Risk of bias - NCT02352948
ipilimumab
phase 2 (phased ipilimumab), 2012ipilimumab + chemotherapyplacebo + chemotherapy -
Reck, 2016ipilimumab + chemotherapyplacebo + chemotherapySCLC - NCT01450761
Govindan, 2017ipilimumab + chemotherapyplacebo + chemotherapy1L Low risk of bias NegativeNCT01285609
nivolumab
CheckMate 057, 2015nivolumabdocetaxel2L, non squamous Risk of bias SuggestingNCT01673867
CheckMate 017, 2015nivolumabdocetaxel2L, squamous Risk of bias SuggestingNCT01642004
CheckMate 026, 2016nivolumabplatinum-based CT1L, PDL1 positive Risk of bias NegativeNCT02041533
CheckMate 227 (nivolumab + CT), 2018nivolumab + CTplatinum-based CT1L, PDL1 negatifSuggestingNCT02477826
CheckMate 227 (High Tumor Mutational Burden), 2018nivolumab + ipilimumabplatinum-based CT1L, hi TMB Risk of bias SuggestingNCT02477826
CheckMate 331 ongoing nivolumabCT - NCT02481830
CheckMate 078 ongoing nivolumabdocetaxel - NCT02613507
CheckMate 153 ongoing nivolumab for 1 yearnivolumab2L Risk of bias - NCT02066636
Checkmate 032 ongoing nivolumab + ipilimumabnivolumab - NCT01928394
CheckMate 451 ongoing nivolumabplacebo - NCT02538666
CheckMate 722 ongoing nivolumab + ipilimumabplatinum-based CT Risk of bias - NCT02864251
CheckMate 227 (nivolumab alone), 2018 ongoing nivolumabplatinum-based CT1L Risk of bias - NCT02477826
pembrolizumab
Keynote 010 2mg, 2015pembrolizumab 2mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 010 10mg, 2015pembrolizumab 10mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 024, 2015pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02142738
KEYNOTE-021 phase 2, 2016pembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous Exploratory SuggestingNCT02039674
Keynote 042 (>=1%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894
Keynote 042 (>=20%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894
Keynote 189, 2018pembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous Low risk of bias ConclusiveNCT02578680
Keynote 407, 2018pembrolizumanb + CTplatinum-based CT1L squamous Risk of bias SuggestingNCT02775435
Keynote 042 (>=50%), 2018pembrolizumabplatinum-based CT1L, PDL1 positiveSuggestingNCT02220894

melanoma

ipilimumab
Hodi (ipi + gp100), 2010ipi + gp100gp1002L Risk of bias SuggestingNCT00094653
Hodi (ipi alone), 2010ipilimumab 3 mg/kggp1002L Risk of bias SuggestingNCT00094653
Robert, 2011ipilimumab + dacarbazinedacarbazine1L Low risk of bias ConclusiveNCT00324155
EORTC 18071 (Eggermont), 2015ipilimumabplaceboadjuvant Low risk of bias Conclusive NCT00636168
nivolumab
CheckMate 037 (Weber), 2015nivolumabchemotherapy2L, anti-CTLA-4 failure Risk of bias SuggestingNCT01721746
CheckMate 066 (Robert), 2015nivolumabdacarbazine1L Low risk of bias Conclusive NCT01721772
CheckMate 067 (nivo vs ipi), 2015nivolumabipilimumab1L Low risk of bias ConclusiveNCT01844505
Postow, 2015nivolumab + ipilimumabipilimumab1L Exploratory - NCT01927419
CheckMate 067 (nivo + ipi vs ipi), 2015nivolumab + ipilimumabipilimumab1L Low risk of bias Conclusive NCT01844505
CheckMate 067 (nivo + ipi vs nivo), 2015nivolumab + ipilimumabnivolumab1L Exploratory - NCT01844505
CheckMate 238, 2017nivolumabipilimumabadjuvant Low risk of bias ConclusiveNCT02388906
pembrolizumab
KEYNOTE-001, 2014pembrolizumab 2mg/kgpembrolizumab 10mg/kg2L Exploratory NegativeNCT01295827
KEYNOTE 002 (2mg/kg Q3W), 2015pembrolizumab 2mg/kgchemotherapy2L Exploratory Suggesting NCT01704287
KEYNOTE 002 (10mg/kg Q3W), 2015pembrolizumab 10mg/kgchemotherapy2L Exploratory SuggestingNCT01704287
KEYNOTE-006 (every 2W), 2015pembrolizumab (every 2W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-006 (every 3W), 2015pembrolizumab (every 3W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-054, 2018pembrolizumabplaceboadjuvant Low risk of bias Conclusive NCT02362594

multiple myeloma

nivolumab
CheckMate 602 ongoing Nivolumab, Elotuzumab, Pomalidomide, dexaM Risk of bias - NCT02726581
pembrolizumab
KEYNOTE-185, 2018pembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCT Risk of bias - NCT02579863
KEYNOTE-183, 2018pembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMM Risk of bias Negative NCT02576977

renal-cell carcinoma (advanced)

atezolizumab
NCT02420821 ongoing atezolizumab + bevacizumab1L Risk of bias - NCT02420821
avelumab
JAVELIN Renal 101 ongoing avelumab + axitinibsunitinib1L, PDL1 positive Risk of bias - NCT02684006
nivolumab
Chekmate 025 (Motzer), 2015nivolumabeverolimus2L Risk of bias SuggestingNCT01668784
CheckMate-214, 2017nivolumab + ipilimumabsunitinib1L Risk of bias ConclusiveNCT02231749
pembrolizumab
KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinib - NCT02853331

urothelial carcinoma (advanced)

atezolizumab
IMvigor211 (IC2/3)atezolizumabchemotherapy2nd line, IC2/3 Risk of bias SuggestingNCT02302807
IMvigor210atezolizumabnil1st and 2nd line Exploratory - NCT02951767
IMVIGOR-130 (monotherapy)atezolizumabcontrolfirst line Risk of bias - NCT02807636
IMVIGOR-130 combination ongoing atezolizumab + CTchemotherapyfirst line - NCT02807636
IMvigor010 ongoing atezolizumabcontroladjuvant Risk of bias - NCT02450331
avelumab
JAVELIN Bladder 100 ongoing avelumabcontrol Risk of bias - NCT02603432
durvalumab
durvalumab phase 1/2durvalumabnil2nd line Exploratory -
DANUBE ongoing durvalumab + tremelimumabchemotherapyfirst line Low risk of bias - NCT02516241
nivolumab
Checkmate 275nivolumabnil2nd line Exploratory - NCT02387996
CHECKMATE 901A ongoing nivolumab + CTchemotherapyfirst line Risk of bias - NCT03036098
CHECKMATE 274A ongoing nivolumabplaceboadjuvant Low risk of bias - NCT02632409
CheckMate 274 ongoing nivolumabplacebofirst line Low risk of bias - NCT02632409
pembrolizumab
Keynote 361 monotherapypembrolizumabchemotherapyfirst line - NCT02853305
KEYNOTE-052, 2017pembrolizumab Exploratory - NCT02335424
KEYNOTE-045, 2017pembrolizumabchemotherapy2nd line Risk of bias SuggestingNCT02256436
Keynote 361 combination ongoing pembrolizumab + CTchemotherapyfirst line - NCT02853305



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons